Nephros (NEPH) Competitors $4.02 -0.06 (-1.47%) Closing price 04:00 PM EasternExtended Trading$4.03 +0.01 (+0.12%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock NEPH vs. INFU, PROF, ELMD, LNSR, BSGM, RCEL, TLSI, LAKE, AVR, and PDEXShould you be buying Nephros stock or one of its competitors? The main competitors of Nephros include InfuSystem (INFU), Profound Medical (PROF), Electromed (ELMD), LENSAR (LNSR), Biosig Technologies (BSGM), Avita Medical (RCEL), TriSalus Life Sciences (TLSI), Lakeland Industries (LAKE), Anteris Technologies Global (AVR), and Pro-Dex (PDEX). These companies are all part of the "medical equipment" industry. Nephros vs. Its Competitors InfuSystem Profound Medical Electromed LENSAR Biosig Technologies Avita Medical TriSalus Life Sciences Lakeland Industries Anteris Technologies Global Pro-Dex Nephros (NASDAQ:NEPH) and InfuSystem (NYSE:INFU) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, valuation, media sentiment, profitability and risk. Which has better earnings & valuation, NEPH or INFU? InfuSystem has higher revenue and earnings than Nephros. Nephros is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNephros$14.16M3.01$70K$0.1233.50InfuSystem$139.89M1.40$870K$0.2341.78 Is NEPH or INFU more profitable? Nephros has a net margin of 7.95% compared to InfuSystem's net margin of 1.12%. Nephros' return on equity of 14.89% beat InfuSystem's return on equity.Company Net Margins Return on Equity Return on Assets Nephros7.95% 14.89% 11.64% InfuSystem 1.12%2.78%1.41% Which has more volatility & risk, NEPH or INFU? Nephros has a beta of 1.11, suggesting that its stock price is 11% more volatile than the S&P 500. Comparatively, InfuSystem has a beta of 1.81, suggesting that its stock price is 81% more volatile than the S&P 500. Does the media favor NEPH or INFU? In the previous week, InfuSystem's average media sentiment score of 0.33 beat Nephros' score of 0.00 indicating that InfuSystem is being referred to more favorably in the news media. Company Overall Sentiment Nephros Neutral InfuSystem Neutral Do institutionals and insiders have more ownership in NEPH or INFU? 41.1% of Nephros shares are held by institutional investors. Comparatively, 71.1% of InfuSystem shares are held by institutional investors. 6.7% of Nephros shares are held by insiders. Comparatively, 10.2% of InfuSystem shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Do analysts rate NEPH or INFU? Nephros currently has a consensus price target of $5.50, indicating a potential upside of 36.82%. InfuSystem has a consensus price target of $12.50, indicating a potential upside of 30.07%. Given Nephros' higher possible upside, equities research analysts plainly believe Nephros is more favorable than InfuSystem.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nephros 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00InfuSystem 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 3 Strong Buy rating(s) 4.00 SummaryInfuSystem beats Nephros on 10 of the 16 factors compared between the two stocks. Get Nephros News Delivered to You Automatically Sign up to receive the latest news and ratings for NEPH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NEPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NEPH vs. The Competition Export to ExcelMetricNephrosMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$42.61M$10.74B$5.74B$9.56BDividend YieldN/A1.89%4.53%4.08%P/E Ratio33.5020.5330.4525.16Price / Sales3.0130.41392.5887.64Price / Cash206.3924.4637.0358.50Price / Book4.423.388.956.21Net Income$70K$211.77M$3.26B$265.38M7 Day Performance0.50%0.86%1.06%-1.13%1 Month Performance12.61%9.94%4.31%-0.71%1 Year Performance117.30%-10.78%28.40%18.89% Nephros Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NEPHNephros1.6596 of 5 stars$4.02-1.5%$5.50+36.8%+120.5%$42.61M$14.16M33.5030INFUInfuSystem3.4056 of 5 stars$8.67+0.8%$12.50+44.2%N/A$179.14M$139.89M146.19410PROFProfound Medical1.7719 of 5 stars$5.62-0.3%$11.00+95.9%-51.1%$168.73M$10.68M-4.60150Earnings ReportELMDElectromed1.7504 of 5 stars$19.140.0%$33.50+75.0%+33.2%$160.76M$61.44M25.56160News CoverageLNSRLENSAR1.0488 of 5 stars$13.04+0.1%$15.00+15.0%+209.1%$153.42M$53.49M-3.09110Positive NewsBSGMBiosig Technologies1.9499 of 5 stars$4.56+11.5%$10.00+119.3%+995.1%$142.87M$40K0.0050Earnings ReportRCELAvita Medical1.445 of 5 stars$5.23+8.7%$12.40+137.1%-47.1%$137.83M$64.25M-2.65130News CoverageTLSITriSalus Life Sciences3.0549 of 5 stars$3.49-2.2%$10.75+208.0%-10.2%$132.06M$29.43M-3.12106Analyst RevisionLAKELakeland Industries4.1518 of 5 stars$13.84+0.6%$26.00+87.9%-38.0%$131.47M$167.21M-4.592,100AVRAnteris Technologies GlobalN/A$3.43-2.0%$16.50+381.0%N/A$123.69M$2.70M0.00138PDEXPro-Dex1.6783 of 5 stars$37.66-2.0%$56.00+48.7%+124.3%$122.77M$53.84M13.45140Positive News Related Companies and Tools Related Companies InfuSystem Competitors Profound Medical Competitors Electromed Competitors LENSAR Competitors Biosig Technologies Competitors Avita Medical Competitors TriSalus Life Sciences Competitors Lakeland Industries Competitors Anteris Technologies Global Competitors Pro-Dex Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NEPH) was last updated on 8/21/2025 by MarketBeat.com Staff From Our PartnersAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nephros Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nephros With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access